Welcome to our dedicated page for Ge Healthcare Technologies SEC filings (Ticker: GEHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GE HealthCare Technologies Inc. filings document formal disclosures for a medical technology and diagnostics company, including Form 8-K reports on results of operations and financial condition, material agreements, capital-structure matters, and governance changes. Recent current reports include earnings releases, a senior unsecured revolving credit facility, and board-related disclosures.
The company’s proxy materials describe annual-meeting matters, director elections, board committee assignments, executive compensation, equity awards, and shareholder voting procedures. GEHC filings also provide formal context for segment performance, liquidity arrangements, credit covenants, and governance matters tied to its healthcare technology, software, and pharmaceutical diagnostics businesses.
GE HealthCare Technologies Inc. director Kevin Lobo reported an open-market purchase of 10,000 shares of common stock at $64.18 per share. After this transaction, he directly owns a total of 14,363 shares of GE HealthCare common stock.
GE HealthCare Technologies Inc. reported that Philip Rackliffe, CEO of AIS, received a grant of 16,458 restricted stock units tied to its common stock. Each unit entitles him to one share at settlement. Half of the units are scheduled to vest on May 15, 2028, and the remaining half on May 15, 2029.
Following this compensation-related award, Rackliffe directly holds 43,187 shares of GE HealthCare common stock. The grant carries no cash exercise price and represents long-term equity-based compensation rather than an open-market stock purchase.
GE HealthCare Technologies Inc. executive Jeannette Bankes, CEO of Patient Care Solutions, reported a routine share withholding related to equity compensation. On May 15, 2026, 5,535 shares of common stock were withheld at $62.67 per share to cover tax obligations from vesting restricted stock units.
This was a tax-withholding disposition, not an open-market sale. Following the transaction, Bankes directly held 38,357 shares of GE HealthCare common stock.
GE HEALTHCARE TECHNOLOGIES INC. Schedule 13G/A shows 31,312,064 shares beneficially owned as of 03/31/2026, representing 6.9% of the outstanding common stock. The filing reports 29,686,614 shares as sole voting power and 31,312,064 shares as sole dispositive power.
The disclosure states these holdings are held on behalf of Dodge & Cox clients, including registered investment companies and managed accounts. The form is signed by the firm’s Chief Compliance Officer on 05/14/2026.
GE HealthCare Technologies Inc. — Capital Research Global Investors filed an amended Schedule 13G reporting beneficial ownership of 21,114,633 shares of common stock, or 4.6% of the 456,290,143 shares believed to be outstanding. The amendment identifies sole voting power for 21,106,720 shares and sole dispositive power for 21,114,633. The filing is signed by a Capital Research officer on 05/11/2026.
GE HealthCare Technologies director Rodney F. Hochman reported a small open-market purchase of company stock. A family trust bought 1,618 shares of common stock at $62.03 per share. Following the transactions, he holds 19,886 shares directly and 1,618 shares indirectly through the family trust.
GE HealthCare Technologies Inc. director Phoebe L. Yang Watkin reported acquiring additional common stock. On May 8, 2026, she made an open-market purchase of 1,000 shares at a weighted average price of $63.0063 per share. After this trade, she directly held 13,702 shares.
On May 7, 2026, she also received an award of 3,586 restricted stock units. Each unit represents the right to receive one share of GE HealthCare common stock, with 100% of the units vesting on the earlier of the company’s next annual stockholders meeting or May 7, 2027, subject to the plan terms and any deferral elections.
CULP H LAWRENCE JR reported acquisition or exercise transactions in this Form 4 filing.
GE HealthCare Technologies Inc. director H. Lawrence Culp Jr. reported equity-based compensation awards rather than open-market trades. He received 4,157 restricted stock units and 3,586 fully vested deferred stock units of common stock, both at no cash cost, as part of director compensation. Following these awards, he holds additional common stock directly and also indirectly through family trusts and a holding company.
GE HealthCare Technologies Inc. director Rodney F. Hochman reported equity awards under the company’s non-employee director plan. On May 7, 2026, he acquired 2,689 restricted stock units that will vest 100% on the earlier of the next annual stockholders’ meeting or May 7, 2027.
He also received 3,586 fully vested deferred stock units in lieu of 100% of his cash retainer, consistent with his election under GE HealthCare’s Non-Employee Director Compensation and Benefits Plan. Each restricted or deferred stock unit represents the right to receive one share of GE HealthCare common stock at settlement.
LESJAK CATHERINE A reported acquisition or exercise transactions in this Form 4 filing.
GE HealthCare Technologies Inc. director Catherine A. Lesjak received an award of 3,586 restricted stock units of GE HealthCare common stock on May 7, 2026. Each unit represents the right to receive one share of common stock at settlement and was granted at no cash cost to her.
The award will vest 100% on the earlier of GE HealthCare’s next annual meeting of stockholders or May 7, 2027. As a result of this compensation-related equity grant, Lesjak’s direct ownership reported in this filing increased to 12,702 shares of common stock, with settlement of vested units potentially deferred under the company’s Non-Employee Director Compensation and Benefits Plan.